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A randomised placebo-controlled trial to differentiate the acute cognitive and 
mood effects of chlorogenic acid from decaffeinated coffee 
Abstract 
In the current study, sixty healthy older adults aged 50 years or older, and who were light to moderate 
coffee drinkers, were administered 6g of a decaffeinated green coffee blend (NESCAFÉ Green Blend 
coffee; GB) or 540mg pure chlorogenic acids (CGA) or placebo in a double-blind acute cross-over design, 
with cognitive and mood assessments pre-dose, 40-mins and 120-mins post-dose. The primary outcome 
measure was accuracy in Rapid Visual Information Processing (RVIP). Secondary cognitive outcome 
measures included RVIP reaction time as well as Inspection time (IT), Jensen Box decision/reaction 
times, serial subtraction and N-Back working memory. Secondary mood measures included Bond-Lader 
and caffeine Research visual analogue scales (VAS). No significant treatment effects were found for the 
primary outcome measure, although significant effects were found amongst secondary measures. 
Overall, CGA in isolation was not found to significantly improve cognitive function relative to placebo 
whereas the GB was found to improve sustained attention as measured by the N-Back task in comparison 
to placebo overall (t=2.45,p=.05), as well as decision time on a 2-choice reaction time task (Jensen box) 
in comparison to placebo at 40 minutes post-dose (t=2.45,p=.05). Similarly, GB was found to improve 
alertness on both the Bond-Lader at 120 minutes relative to CGA (t=2.86, p=0.02) and the caffeine 
Research VAS relative to CGA (t=3.09, p=0.009) and placebo (t=2.75,p=0.02) at 120 minutes post-dose. 
Both the GB and CGA were also found to significantly improve symptoms of headache at 120 minutes 
relative to placebo (t=2.51,p=0.03 and t=2.43,p=.04 respectively), whilst there was a trend towards a 
reduction in jitteriness with GB and CGA in comparison to placebo at 40 minutes post-dose 
(t=2.24,p=0.06 and t=2.20,p=0.06 respectively). These findings suggest that the improvements in mood 
observed with GB, but not the improvements in cognitive function, are likely to some extent to be 
attributable to CGAs. 
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Abstract
In the current study, sixty healthy older adults aged 50 years or older, and who were light to moderate coffee
drinkers, were administered 6g of a decaffeinated green coffee blend (NESCAFÉ Green Blend coffee; GB) or 540mg
pure chlorogenic acids (CGA) or placebo in a double-blind acute cross-over design, with cognitive and mood
assessments pre-dose, 40-mins and 120-mins post-dose. The primary outcome measure was accuracy in Rapid
Visual Information Processing (RVIP). Secondary cognitive outcome measures included RVIP reaction time as well
as Inspection time (IT), Jensen Box decision/reaction times, serial subtraction and N-Back working memory.
Secondary mood measures included Bond-Lader and caffeine Research visual analogue scales (VAS). No significant
treatment effects were found for the primary outcome measure, although significant effects were found amongst
secondary measures. Overall, CGA in isolation was not found to significantly improve cognitive function relative to
placebo whereas the GB was found to improve sustained attention as measured by the N-Back task in comparison to
placebo overall (t=2.45,p=.05), as well as decision time on a 2-choice reaction time task (Jensen box) in comparison
to placebo at 40 minutes post-dose (t=2.45,p=.05). Similarly, GB was found to improve alertness on both the Bond-
Lader at 120 minutes relative to CGA (t=2.86, p=0.02) and the caffeine Research VAS relative to CGA (t=3.09,
p=0.009) and placebo (t=2.75,p=0.02) at 120 minutes post-dose. Both the GB and CGA were also found to
significantly improve symptoms of headache at 120 minutes relative to placebo (t=2.51,p=0.03 and t=2.43,p=.04
respectively), whilst there was a trend towards a reduction in jitteriness with GB and CGA in comparison to placebo
at 40 minutes post-dose (t=2.24,p=0.06 and t=2.20,p=0.06 respectively). These findings suggest that the
improvements in mood observed with GB, but not the improvements in cognitive function, are likely to some extent to
be attributable to CGAs.
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Introduction
Coffee is one of the most widely consumed beverages
throughout the world. The physiological and behavioural effects
of coffee (with caffeine) have been extensively studied over the
past four decades with research generally demonstrating that
caffeine exerts positive effects on cognitive performance,
including measures of reaction time (RT), alertness, and
vigilance [1-9]. In contrast, little is known regarding the
cognitive and mood effects of non-caffeine constituents of
coffee, as their effects are difficult to dissociate from those of
caffeine. This is due in part to the significant effects on brain
function which are exerted by caffeine alone [10,11], but is also
due to the effects of non-caffeine compounds in modulating or
even opposing those of caffeine [12]. For this reason the acute
effects of other compounds found in coffee are difficult to
observe, except in decaffeinated coffee.
Chlorogenic acids (CGA) are polyphenolic compounds which
make up 7-9% of coffee by weight, in contrast to caffeine which
makes up as little as 1% [13]. CGAs include caffeoylquinic
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 acid, feruloylquinic acid, dicaffeoylquinic acid and smaller
quantities of p-coumaroylquinic acid. CGAs from a variety of
plant sources have been shown to exert cardio-protective and
anti-oxidant effects as well as the inhibition of lipid peroxidation
[14-24]. A recent study by Kwon et al. [25] which used a
scopolamine animal model of amnesia, showed that CGAs
inhibit acetylcholinesterase activity in vitro. Through effects on
serotonin transmission, CGAs have also been shown to exert
anxiolytic effects in an animal model of restraint stress [26].
In a recent exploratory trial from our laboratory [27], it was
found that a decaffeinated green coffee blend (NESCAFÉ
Green Blend coffee) high in CGAs (521mg) exerted a number
of trend-level effects on cognition and mood, including
increased alertness and decreased headaches and mental
fatigue in comparison to regular decaffeinated coffee. As CGAs
are the most abundant family of compounds found in
decaffeinated green blend coffee, it is feasible that the positive
cognitive and mood effects observed in the study by Cropley et
al. [27] are attributable to CGAs. To further explore this
possibility, the present study aimed to assess the effect of pure
CGA on cognitive function and mood in a healthy older
population. To better understand whether it is the CGAs in the
decaffeinated green coffee blend that are attributed to the
positive effects, a second aim was to compare the effects of
pure CGA with the decaffeinated green coffee blend. If it is
CGAs contributing to the positive effects, no difference in
cognitive performance and mood between pure CGA and
decaffeinated green blend coffee is expected. Finally, as the
results from the initial acute clinical trial [27] were the first
indication that a non-caffeinated pure coffee may improve
cognitive performance, the third aim was to replicate and
confirm the previous findings and show that six grams of
decaffeinated green blend coffee improves attention and mood
in a healthy older population. To address these research aims,
Rapid Visual Information Processing (RVIP) accuracy was
used as the primary outcome, and a range of secondary
cognitive and mood measures were also used in order to
explore differential treatment effects associated with
decaffeinated green blend coffee in comparison to pure CGA.
Methods
Participants
112 Participants were initially screened to take part in the
study, resulting in 65 patients who met inclusion criteria and
were randomized to receive treatments. Out of those
randomized, 60 participants completed and were included in
the final analysis. Demographic characteristics of participants
at baseline are displayed in Table 1 and the trial design is
detailed in Figure 1. Sample size was calculated on the basis
of power analysis using previous data from our laboratory [27]
regarding the primary outcome measure of RVIP accuracy (see
below). The estimated effect size for RVIP accuracy was an
increased score of 2.45 points for decaffeinated coffee from
green beans in comparison to placebo, with a within-subject
SD of 6.52 points. Using this effect size, and assuming 80%
power of detecting this effect in a repeated-measures design, a
sample size of N=58 was calculated according to a 5% (two-
tailed) significance level.
All participants were healthy older adults aged 50+ years, as
well as being light to moderate coffee drinkers (i.e. with
caffeine) drinking no more than 16 cups of coffee per week.
Participants without any existing or pre-existing physical or
neurological conditions, no history of psychiatric, cardiac,
endocrine, gastrointestinal, or bleeding disorders, not taking
any medication that could potentially affect the outcome of the
study (i.e. psychoactive medication) including drugs, excessive
amounts of alcohol, and non-smokers, were included in the
study. An MMSE score of 27 or higher was an additional
inclusion criterion, and was taken as evidence of normal
cognitive functioning. Participants were also required to abstain
from any caffeine-containing or CGA-rich drinks or food
products for 24 hours prior to each testing session. All
participants provided written informed consent and the study
was approved by the Swinburne University Ethics Committee.
Australia New Zealand clinical trials registration number:
ACTRN12611000067976. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Study design and treatments
The study was an acute-dose cross-over, placebo-controlled,
double blind, randomized, single centre, clinical trial with three
treatment conditions: Chlorogenic acid (CGA), decaffeinated
green blend coffee and placebo. The CGA treatment consisted
of 540mg chlorogenic acid mixed in a placebo matrix of 5460
mg maltodextrin and a soluble powder derived from rice cereal
(CHE; Cereals Hydrolzed Enzymatically). Coffee flavour and
colour were added in order to maintain treatment blinding. The
placebo treatment consisted of 6g maltodextrin and CHE, also
with coffee flavour and colouring. Decaffeinated green blend
coffee (NESCAFÉ Green Blend, Nestlé Switzerland), is a
soluble coffee manufactured from a blend of decaffeinated
Table 1. Participant baseline demographic characteristics.
Gender  
 Male 43% (26)
 Female 57% (34)
Age (years)  
 Lower quartile 60
 Median 64.5
 Upper quartile 68
Education  
 < 4 years 5% (3)
 4 - 8 years 30% (18)
 8-9 years 13% (8)
 > 10 years 52% (31)
Body Mass Index  
 Lower quartile 22.8
 Median 24.6
 Upper quartile 27.325
doi: 10.1371/journal.pone.0082897.t001
Effects of Chlorogenic Acid on Cognition and Mood
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green and roasted coffee beans, resulting in an increased CGA
content in comparison to regular coffee. 6g of green blend
coffee was administered in the current study. For each of the
three treatments, the composition of chlorogenic acids and
caffeine are listed in Table 2. The CGA and green blend
decaffeinated coffee treatments were well-matched for total
CGA dosage, whilst the difference in caffeine dosage between
treatments was small (3.8mg). All treatments were in powdered
form and were dissolved and administered as a normal hot
coffee drink. One coffee sachet (6 grams) was dissolved in 300
milliliters of boiled water, with milk and saccharine added by
participants to suit their own taste. The addition of milk to black
coffee has not been found to affect the bioavailability of
decaffeinated green blend coffee [28]. The three treatments
were coded as A, B and C and a randomization schedule for
each subject was generated using Williams Design in R 2.6.1
by a Nestle Biostatistician not involved in the study.
Cognitive measures
Rapid Visual Information Processing (RVIP).  The RVIP
task is a test of sustained attention which loads heavily on
working memory. Single digits (1-9) are presented continuously
in the middle of a computer screen in a semi-random order.
Participants are required to press the response button as soon
Figure 1.  Trial Profile Plot.  
doi: 10.1371/journal.pone.0082897.g001
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as they detect three consecutive odd or three even digits in
ascending order (i.e. 2,4,6; 3,5,7; 4,6,8; 5,7,9). The digits are
presented at a rate of 100 digits per minute. Stimulus duration
is 600ms with no inter-stimulus interval. There are eight target
sequences (i.e. potential correct hits) presented per minute (96
targets in total). The total duration of the task is 12 minutes.
The outcome measures are the total number of correct hits
(accuracy), reaction time for correct hits and false alarm rate.
RVIP accuracy was used as the primary outcome measure.
N Back Task.  The N-Back task is a measure of sustained
and selective attention and impulsivity. Single digits are
presented on the screen. Participants are required to press
‘YES’ or ‘NO’ using a button box, to indicate whether the digit is
the same as the n previously (e.g. 1-back the previous digit, 3-
back the digit 3 previously). The task is scored for speed and
accuracy and the task duration is approximately 4 minutes.
Inspection Time (IT).  The IT task is a measure of
perceptual speed. This task assesses the presentation time
that a subject requires to discriminate between two possible
stimuli. The task consists of a stimulus with two vertical parallel
lines joined at the top by a horizontal line. There are two
versions of the stimulus; either the left line is shorter than the
right or the right line is shorter than the left. Stimuli are flashed
on a computer screen and the participant is instructed to press
a key corresponding to the side of the symbol that is shorter.
Each stimulus presentation is followed by the presentation of a
backward visual mask. This prevents further processing of the
stimulus in iconic memory. The speed of stimulus presentation
is varied according to the accuracy of the participants’
responses. The length of presentation of the backward visual
mask also varies to determine the optimal visual encoding time.
The objective is to respond as accurately, rather than as
quickly, as possible. The duration of stimulus presentation is
varied until an 80% accuracy level is obtained by the
participant. This is taken as the outcome measure for speed of
visual information processing speed.
Table 2. Composition of the study coffee treatments per
serving (mg/g).
  Green Blend decaffeinated coffee CGA Placebo
Chlorogenic acids (mg/g) 88.6 93.0 0.00
 3-CQA 20.1 15.2 0.00
 4-CQA 23.5 24.3 0.00
 5-CQA 25.8 25.6 0.00
 3,4di-CQA 3.2 6.0 0.00
 3,5di-CQA 1.8 3.6 0.00
 4,5di-CQA 2.8 5.5 0.00
 4-FQA 4.2 5.4 0.00
 5-FQA 7.2 7.4 0.00
 Caffeic acid 0.1 0.9 0.00
Caffeine (mg/g) 0.8 1.6 0.1
Per Serving (6g) (5.7g) (6g)
Total CGAs (mg/cup) 532 530 0.0
Total Caffeine(mg/cup) 5.0 8.8 0.7
Total CGAs and Caffeine according to cup.
doi: 10.1371/journal.pone.0082897.t002
Jensen Box.  The Jensen Box is an apparatus that
distinguishes simple and choice decision time and movement
time from total reaction time. This apparatus has eight lights
which are arranged in a semi-circular configuration. A response
button is located adjacent to each light. A "home" button is
situated in the centre of the panel. Participants were required to
keep the home button pressed down until a target light
appeared. When the target light appeared they were then
required to release the home button as quickly as possible and
press the response button adjacent to the stimulus light.
Decision time (DT) was defined as the time from stimulus onset
to the release of the home button, and movement time (MT) as
the time from release of the home button to the depression of
the stimulus button. Choice was manipulated by varying the
number of stimulus alternatives, from 0 (i.e. one light at one
possible location) to multiple (i.e. the stimulus may appear in
any one of the eight light positions). Participants were given
several practice trials in the eight stimulus (i.e. eight lights)
condition so that they could familiarise themselves with the
task. DTs of less than 150 ms were discarded as outliers, as it
has been argued that physiological limits prevent shorter DTs
(Jensen, 1987). DTs over 999 ms were also discarded and
replaced with an additional trial. In addition, all DTs exceeding
three SDs above the subject's mean DT were also discarded
(Jensen, 1987). The outcome measures were the mean DTs
and MTs for all four choices: 1, 2, 4 and 8.
Serial Threes and Sevens.  Serial sevens is a computerised
task measuring concentration and working memory. A random
starting number between 800 and 999 is presented on the
computer screen. Participants are required to count backwards
in sevens from the given number, as quickly and as accurately
as possible, with responses made using a numeric keyboard.
The outcome measures are the total number of subtractions
and number of errors. The duration of the task is 2 minutes.
Serial Threes is identical to Serial Sevens except that it
requires serial subtractions of threes. The duration of the task
is also 2 minutes.
Mood measures
Bond-Lader Visual Analogue Mood Scales (B-L
VAS).  The B-L scales provide self-evaluation of mood. In total,
16 dimensions of mood are given: Alert-Drowsy, Calm-Excited,
Strong-Feeble, Muzzy-Clear headed, Well Coordinated-
Clumsy, Lethargic-Energetic, Contented-Discontented,
Troubled-Tranquil, Mentally Slow-Quick Witted, Tense-
Relaxed, Attentive-Dreamy, Incompetent-Proficient, Happy-
Sad, Antagonistic-Friendly, Interested-Bored, Withdrawn-
Social. The participant is required to mark, on a 100 mm line to
what extent the described state is appropriate to him/her at that
moment in time. The individual responses from the 16 mood
scales are combined to make three affective dimensions of
alertness, contentment, and calmness.
Caffeine Research Visual Analogue Scales (Caff-
VAS).  The Caff-VAS scales consist of seven visual analogue
scales ("relaxed", "alert", "jittery", "tired", "tense", "headache",
overall mood") that have previously been used in research into
the effects of caffeine (Rogers et al., 2003). In addition, a single
"mentally fatigued" visual analogue scale was included, as
Effects of Chlorogenic Acid on Cognition and Mood
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previous research has shown it to be sensitive to a caffeine-
glucose drink (Kennedy & Scholey, 2004).
Statistical analysis
All statistical analyses were conducted using SAS 9.2 with
linear mixed modelling (PROC MIXED). The multivariate
correlated error approach was used, whereby within-subject
parameter estimates of residual covariance were estimated for
each combination of time and treatment. The Residual
Maximum Likelihood estimation method (REML) was used with
unstructured (UN) covariance and a between-within degrees of
freedom method. Fixed terms were fitted for the Treatment
Effect (Placebo, Green Blend, CGA) and Time since dosing (40
mins, 120 mins). Pre-dose performance was fitted as a
covariate and the interaction of Treatment*Visit was specified
as the repeated term. Post-hoc differences of least squares
means were used to determine significant differences between
treatment groups overall, as well as at individual time points
(40 min and 120 min). At each timepoint (40 min and 120 min)
significance values for least square means comparing the three
treatment groups were adjusted for multiplicity using the
Hommel method. An adjusted alpha level of 0.05 was set for
statistical significance of least square differences, however to
allow greater exploration of the data any least square
differences associated with corrected p-values <.10 were taken
as trend level and have also been discussed in text. Cohen’s d
effect sizes were calculated for significant differences of least
square means.
Procedure
A short telephone interview was conducted with all potential
subjects to ensure study criteria were met. Successful
volunteers attended one training session. Participants were
asked to abstain from alcohol, caffeinated and CGA-rich foods/
beverages, and to consume foods with low polyphenol content
for 24 hours prior to each testing session. During the training
session participants completed demographic and medical
questionnaires, the Mini Mental State Examination (MMSE),
and signed informed consent forms (if criteria met). Following
this, participants completed the battery of cognitive tests to
minimize procedural learning effects and familiarize subjects
with study measures. Participants attended four study visits
separated by a one week washout period. The first visit was a
training session (V0), and the remaining three experimental
sessions (V1, V2, V3) participants were randomized to receive
CGA, decaffeinated Green Blend or placebo. Cognitive and
mood assessments were conducted at three time points for
each study visit: before treatment (pre-dose), 40 minutes and
120 minutes after treatment (post-dose). Individual assignment
to the order of treatment condition was randomized and
counterbalanced according to stratification per gender. This
was provided as a list by the Nestlé Research Centre (NRC)
biostatistician.
At the beginning of each experimental session, a sandwich
(containing salad with either cheese or chicken) and water
were provided. After the participant finished eating, subjects
completed the mood visual analogue scales followed by the
cognitive tests. The mood scales were completed a second
time immediately after baseline cognitive testing. The battery of
tests were approximately 40 minutes’ duration. Subjects were
then administered the equivalent of three servings of coffee,
consumed within 15 minutes. Based on a previous
pharmacokinetic study conducted at Nestlé, following oral
ingestion of decaffeinated NESCAFÉ Green Blend soluble
coffee, several polyphenol metabolites were shown to peak in
plasma within two hours after coffee ingestion [29]. Based on
these results and the results from the previous pilot
decaffeinated coffee trial from our laboratory [27], cognitive and
mood testing began 40 minutes after treatment consumption.
Participants rested for approximately 15 minutes before the
final battery of cognitive and mood tests were administered 120
minutes following treatment consumption. All data was
collected at Swinburne University of Technology, Hawthorn,
Australia between November 2010 and July 2011. Each
experimental session took approximately four hours to




Means and standard errors of responses on all cognitive
outcome measures are displayed in Table 3 according to
treatment group. Significant differences in cognitive outcome
measures between treatment groups at 40 minute and 120
minute time points are displayed in Figure 2.
Rapid Visual Information Processing (RVIP).  Two
participants were removed from analysis due to zero percent
accuracy on at least one of the time points. Mixed ANCOVA
adjusting for baseline scores and considering time, treatment
and their interaction as independent variables were fitted for
accuracy, reaction time (RT) and number of false alarms. No
significant treatment effect or interaction with time was found
for the primary outcome measure RVIP accuracy, or for RVIP
reaction time. However, differences of least square means
revealed that at 120 minutes post-dose there was a trend
towards RT being slower with CGA consumption in comparison
to placebo (t=-2.25, p=.08, d=0.42).
Inspection (IT).  Box-cox transformation was applied to IT
responses (Lambda = -0.5) in order to normalize the data prior
to analysis. Mixed ANCOVA adjusting for baseline IT and
considering time, treatment and their interaction as
independent variables were fitted to responses. No significant
treatment effect or interaction with time was found, although
differences of least square means revealed that at 120 minutes
post-dose IT was significantly slower with CGA consumption in
comparison to placebo (t=-2.26, p=.08, d=0.41).
Jensen Task - Decision Time (DT).  Box-cox transformation
was applied to all DT responses (Lambda=0, LN) in order to
normalize the data prior to analysis. Mixed ANCOVA adjusting
for baseline scores and considering time, treatment and their
interaction as independent variables were fitted for 1-choice, 2-
choice, 4-choice and 8-choice DT. For 2-choice DT there was a
trend towards an interaction between treatment and time
(F(2,59)=2.36,p=0.10), with differences of least square means
revealing a trend towards DT being faster with decaffeinated
Effects of Chlorogenic Acid on Cognition and Mood
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Table 3. Means (±SE) of cognitive outcome measures.
 Treatment N pre-dose 40 mins 120 mins
RVIP -Accuracy
(%)
Placebo 58 44.94 (2.64) 44.04 (2.65) 43.28 (2.87)
 Green Blend 58 45.03 (2.72) 45.46 (2.76) 44.79 (2.87)
 CGA 58 46.52 (2.79) 44.54 (2.91) 44.49 (2.83)
RVIP -RT (ms) Placebo 58 541.8 (7.63) 542.3 (7.64) 544.5 (7.99)
 Green Blend 58 548.3 (7.32) 547.0 (7.26) 551.3 (7.95)
 CGA 58 547.5 (7.53) 549.4 (7.48) 557.6 (8.08)
RVIP -False
Alarms
Placebo 58 19.43 (4.23) 21.79 (4.63) 19.43 (4.30)
 Green Blend 58 17.60 (2.83) 24.50 (5.23) 23.00 (5.30)
 CGA 58 18.55 (2.90) 23.90 (5.85) 16.53 (2.93)
Inspection Time
(ms)





 Green Blend 60 92.92 (5.14) 96.04 (4.72) 105.2 (7.37)





Placebo 60 331.9 (7.89) 335.4 (6.86) 339.0 (8.16)
 Green Blend 60 332.7 (7.75) 340.4 (8.35) 339.7 (7.65)

























Placebo 60 342.9 (7.49) 354.9 (6.99) 351.3 (7.51)
 Green Blend 60 354.2 (8.33) 350.7 (7.70) 356.9 (7.53)


























Placebo 60 363.5 (7.76) 369.4 (7.67) 372.1 (8.27)
 Green Blend 60 368.9 (8.04) 365.4 (7.35) 370.4 (7.10)





























427.9 (9.03) 416.2 (7.89)




















green blend coffee in comparison to placebo at 40 minutes
(t=2.45,p=.05, d=0.45). For 4-choice DT there was a trend
towards a main effect for treatment F(2,59)=2.58,p=.08),
although no significant between group differences were found
with least squares means. For 8-choice DT there was a
significant Treatment x time interaction (F(2,59)=3.78,p=0.03),
with differences of least square means revealing a trend
towards DT being slower with green blend coffee in
comparison to placebo at 120 minutes (t=-2.27,p=.08, d=0.41).
Jensen Task - Movement Time (MT).  Box-cox
transformation was applied to all MT responses (Lambda = 0,
LN) in order to normalize the data prior to analysis. Mixed
ANCOVA adjusting for baseline scores and considering time,
treatment and their interaction as independent variables were
fitted for 1-choice, 2-choice, 4-choice and 8-choice MT. For 2-
choice MT there was a trend towards an interaction between
treatment and time (F(2,59)=2.74,p=0.07), although no
significant between group differences were found with least
squares means. For 4-choice MT there was a trend towards a
main effect for treatment (F(2,59)=2.58,p=0.08), although no
significant between groups differences were found with least
squares means.
Serial 3s and 7s subtraction.  Box-cox transformation was
applied to RTs (Lambda = -0.5) as well as Total Correct
(Lambda = +0.5) in order to normalize the data prior to
Table 3 (continued).
 Treatment N pre-dose 40 mins 120 mins
















Placebo 60 26.67 (1.42) 27.48 (1.34) 27.88 (1.37)
 Green Blend 60 26.51 (1.62) 27.59 (1.54) 28.25 (1.52)
 CGA 60 26.97 (1.40) 27.65 (1.46) 28.42 (1.56)
Serial 3s -RT
(ms)
Placebo 60 4782 (268.2) 4404 (196.7) 4415 (227.2)
 Green Blend 60 4828 (289.0) 4457 (227.0) 4572 (253.3)
 CGA 60 4732 (259.5) 4436 (228.1) 4370 (222.6)
Serial 7s -
Correct
Placebo 60 18.98 (1.13) 18.40 (1.16) 19.13 (1.15)
 Green Blend 60 18.90 (1.16) 18.68 (1.22) 19.31 (1.24)
 CGA 60 18.33 (1.18) 18.97 (1.20) 19.66 (1.12)
Serial 7s -RT
(ms)
Placebo 60 6597 (396.4) 6554 (375.5) 6563 (408.7)
 Green Blend 60 6663 (404.3) 6875 (528.4) 6493 (404.0)
 CGA 60 6671 (458.1) 6628 (430.6) 6313 (403.8)
N-Back -
Accuracy (%)
Placebo 60 83.22 (1.14) 83.26 (1.22) 83.44 (1.16)
 Green Blend 60 81.67 (1.26) 83.82 (1.01) 83.22 (1.21)
 CGA 60 81.59 (1.21) 82.41 (1.11) 84.52 (1.12)
N-Back -RT (ms) Placebo 60 1142 (52.84) 1137 (57.55) 1086 (52.48)
 Green Blend 60 1131 (53.98) 1041 (46.93) 1013 (47.35)
 CGA 60 1125 (52.75) 1076 (58.43) 1048 (45.78)
doi: 10.1371/journal.pone.0082897.t003
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analysis. Mixed ANCOVA adjusting for baseline scores and
considering time, treatment and their interaction as
independent variables were fitted for RTs and total numbers
correct. No significant treatment effect or interaction with time
was found for RTs or total correct in either Serial 3s or Serial
7s.
N-Back.  Box-cox transformation was applied to RT (Lambda
= 0, LN) in order to normalize the data prior to analysis. Mixed
ANCOVA adjusting for baseline scores and considering time,
treatment and their interaction as independent variables were
fitted for RTs and Accuracy. A significant main effect for
treatment was found F(2,59)=3.12,p=.05), with differences of
least square means revealing faster RT with Green Blend in
comparison to placebo (averaged across both time points)
(t=2.45,p=.05, d=0.45). For N-Back accuracy, a trend towards
an interaction between treatment and time was found
(F(2,59)=2.71,p=.07), although no significant between group
differences were found with least square means.
Mood outcome measures
Means and standard errors of responses on all mood
outcome measures are displayed in Table 4 according to
treatment group. Significant differences in mood outcome
measures between treatment groups at 40 minute and 120
minute time points are displayed in Figure 3.
Bond-Lader Alert.  ANCOVA adjusting for baseline scores
and considering time, treatment and their interaction as
independent variables were fitted for Bond-Lader Alert scores
both before cognitive testing (pre-test) and after cognitive
testing (post-test). For pre-test Alert scores no significant
treatment effect or interaction with time was found. However,
for post-test Alert scores a significant treatment effect was
revealed (F(2,59)=4.18,p=.02). Differences of Least Square
Means revealed that Alertness was significantly greater with
decaffeinated green blendcoffee in comparison to CGA overall
(t=2.89, p=.02, d=0.53). At 40 minutes there was a trend
towards Alertness being greater with decaffeinated green blend
coffee in comparison to CGA (t=2.41, p=.06, d=0.44). At 120
minutes Alertness was found to be significantly greater with the
green blend coffee in comparison to CGA (t=2.86, p=.02,
d=0.52) and there was also a trend towards Alertness being
greater with the green blend coffee in comparison to placebo
(t=-2.16, p=.07, d=0.39).
Bond-Lader Content.  Box-cox transformation was applied
to pre-test content scores (Lambda = +2) as well as post-test
content scores (Lambda = +1.5) in order to normalize the data
prior to analysis. ANCOVA adjusting for baseline scores and
considering time, treatment and their interaction as
independent variables were fitted for Bond-Lader Content
scores both before cognitive testing (pre-test) and after
cognitive testing (post-test). For pre-test Content scores no
significant treatment effect or interaction with time was found.
However, for post-test Content scores a trend towards a main
effect for treatment was found (F(2,59)=2.85,p=.07).
Differences of Least Square Means revealed a trend towards
contentedness being greater with placebo in comparison to
CGA overall (t=2.33, p=.07, d=0.42). At 40 minutes
Contentedness was found to be significantly greater with
Placebo in comparison to placebo (t=2.86, p=.02, d=0.52).
Figure 2.  Significant Treatment effects on Cognitive Measures.  † p<.10, * p<.05, p<.01.
doi: 10.1371/journal.pone.0082897.g002
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Table 4. Means (±SE) of mood outcome measures.
 Treatment N pre-dose 40 mins 120 mins
Bond-Lader Alert Placebo 60 69.61 (2.04) 71.08(2.18) 67.73 (2.06)
(PRE) Green Blend 60 69.20 (2.07) 72.78 (2.01) 68.30 (2.41)
 CGA 60 65.69 (2.22) 71.00 (2.20) 68.39 (2.30)
Bond-Lader Alert Placebo 60 64.06 (2.48) 59.90 (2.75) 56.76 (2.64)
(POST) Green Blend 60 63.48 (2.53) 61.49 (2.60) 59.51 (2.72)
 CGA 60 66.29 (2.35) 59.95 (2.59) 57.09 (2.61)
Bond-Lader Content Placebo 60 80.06 (1.52) 79.25 (1.73) 76.76 (2.00)
(PRE) Green Blend 60 78.20 (1.76) 77.79 (1.81) 76.69 (1.99)
 CGA 60 78.93 (1.58) 77.78 (1.87) 77.85 (1.87)
Bond-Lader Content Placebo 60 73.22 (2.16) 73.00 (2.26) 72.78 (2.27)
(POST) Green Blend 60 73.08 (2.20) 72.35 (2.27) 72.46 (2.33)
 CGA 60 74.58 (2.07) 71.22 (2.36) 72.22 (2.32)
Bond-Lader Calm Placebo 60 75.29 (1.87) 73.84 (2.09) 71.66 (2.20)
(PRE) Green Blend 60 75.07 (1.84) 73.37 (1.98) 72.20 (2.18)
 CGA 60 74.88 (1.85) 74.93 (2.02) 72.59 (2.07)
Bond-Lader Calm Placebo 60 66.90 (2.41) 67.23 (2.59) 67.88 (2.42)
(POST) Green Blend 60 67.70 (2.48) 67.30 (2.23) 66.75 (2.65)
 CGA 60 68.16 (2.56) 67.40 (2.27) 67.10 (2.50)
CaffVAS Alertness Placebo 60 70.70 (2.25) 68.67 (2.35) 63.07 (2.37)
(PRE) Green Blend 60 69.30 (2.49) 69.88 (2.37) 65.08 (2.81)
 CGA 60 68.57 (2.67) 68.25 (2.47) 62.10 (2.92)
CaffVAS Alertness Placebo 60 62.67 (2.76) 57.12 (2.74) 51.40 (2.84)
(POST) Green Blend 60 60.20 (2.95) 58.42 (2.95) 56.65 (2.81)
 CGA 60 61.95 (2.78) 55.95 (3.11) 49.43 (2.80)
CaffVAS Relaxation Placebo 60 71.42 (2.58) 72.95 (2.17) 70.30 (2.19)
(PRE) Green Blend 60 72.62 (2.47) 70.55 (2.42) 68.07 (2.63)
 CGA 60 73.05 (2.33) 71.65 (2.44) 67.33 (2.62)
CaffVAS Relaxation Placebo 60 64.02 (2.77) 63.23 (2.95) 63.27 (2.64)
(POST) Green Blend 60 65.22 (2.75) 62.27 (2.91) 65.73 (2.87)
 CGA 60 65.33 (2.68) 60.40 (3.25) 59.65 (2.96)
CaffVAS Mental
Fatigue
Placebo 60 21.65 (2.21) 31.72 (2.79) 37.08 (2.69)
(PRE) Green Blend 60 21.73 (2.48) 32.62 (3.03) 37.42 (3.18)
 CGA 60 22.75 (2.67) 29.73 (2.76) 37.77 (3.33)
CaffVAS Mental
Fatigue
Placebo 60 37.58 (3.11) 44.77 (3.11) 52.02 (3.23)
(POST) Green Blend 60 38.22 (3.14) 45.31 (3.30) 48.67 (3.29)
 CGA 60 37.22 (3.06) 45.62 (3.10) 53.55 (3.10)
CaffVAS Tiredness Placebo 60 26.50 (2.27) 34.03 (2.84) 40.45 (2.62)
(PRE) Green Blend 60 26.75 (2.60) 32.92 (2.71) 36.25 (2.67)
 CGA 60 29.62 (2.93) 33.33 (2.74) 36.97 (2.69)
CaffVAS Tiredness Placebo 60 38.38 (2.89) 47.13 (3.02) 49.95 (2.83)
(POST) Green Blend 60 35.98 (2.81) 44.39 (3.23) 46.63 (3.00)
 CGA 60 34.95 (2.82) 39.80 (2.76) 50.45 (2.81)
CaffVAS Jittery Placebo 60 14.45 (1.57) 18.97 (2.24) 17.70 (2.14)
(PRE) Green Blend 60 18.97 (2.18) 16.32 (1.79) 17.10 (2.06)
 CGA 60 18.73 (2.26) 16.35 (1.94) 18.10 (2.12)
CaffVAS Jittery Placebo 60 22.15 (2.62) 21.90 (2.50) 18.33 (2.15)
(POST) Green Blend 60 20.37 (2.38) 19.76 (2.49) 20.47 (2.55)
 CGA 60 20.85 (2.44) 19.30 (2.33) 21.17 (2.68)
CaffVAS Headache Placebo 60 13.07 (2.09) 15.58 (2.44) 19.00 (2.69)
(PRE) Green Blend 60 16.23 (2.63) 16.02 (2.74) 20.87 (3.27)
 CGA 60 13.65 (2.06) 15.82 (2.39) 17.42 (2.70)
CaffVAS Headache Placebo 60 15.03 (2.34) 16.38 (2.45) 21.22 (2.98)
Bond-Lader Calm.  Box-cox transformation was applied to
pre-test calmness scores (Lambda = +1.5) in order to
normalize the data prior to analysis. ANCOVA adjusting for
baseline scores and considering time, treatment and their
interaction as independent variables were fitted for Bond-Lader
Calm scores both before cognitive testing (pre-test) and after
cognitive testing (post-test). No significant treatment effects or
interactions with time were either pre or post-test.
Caffeine-VAS Alert.  ANCOVA adjusting for baseline scores
and considering time, treatment and their interaction as
independent variables were fitted for Caff-VAS Alert scores
both before cognitive testing (pre-test) and after cognitive
testing (post-test). Pre-test no significant treatment effects or
interaction with time was found. However, post-test a
significant main effect for Treatment was revealed
(F(2,59)=3.40,p=.04). Differences of Least Square Means
revealed that there was a trend towards Alertness being
greater with decaffeinated green blend coffee in comparison to
CGA (t=2.41,p=.05, d=0.44) and placebo (t=2.21,p=.06,
d=0.40) overall. At 120 minutes Alertness was found to be
significantly greater with the green blend coffee in comparison
to placebo (t=2.75, p=.02, d=0.50) and with green blend coffee
in comparison to CGA (t=3.09, p=.009, d=0.56).
Caffeine-VAS Relaxed.  Box-cox transformation was
applied to pre-test relaxation scores (Lambda = +2) in order to
normalize the data prior to analysis. ANCOVA adjusting for
baseline scores and considering time, treatment and their
interaction as independent variables were fitted for Caff-VAS
Relaxed scores both before cognitive testing (pre-test) and
after cognitive testing (post-test). No significant treatment
effects or interaction with time were found either pre or post-
test. However differences of Least Square Means revealed that
at 120 minutes Relaxation was significantly greater with
decaffeinated green blend coffee in comparison to CGA
(t=2.75,p=.02, d=0.50).
Table 4 (continued).
 Treatment N pre-dose 40 mins 120 mins
(POST) Green Blend 60 18.98 (3.09) 17.68 (2.98) 19.95 (3.35)
 CGA 60 17.18 (2.32) 18.20 (2.61) 17.18 (2.49)
CaffVAS Tension Placebo 60 19.85 (1.98) 20.97 (2.12) 26.03 (2.41)
(PRE) Green Blend 60 20.78 (2.14) 22.33 (2.46) 22.47 (2.36)
 CGA 60 19.85 (2.04) 21.42 (2.10) 24.78 (2.47)
CaffVAS Tension Placebo 60 29.85 (2.79) 29.37 (2.84) 31.27 (3.00)
(POST) Green Blend 60 27.23 (2.54) 28.44 (3.06) 30.82 (3.26)
 CGA 60 30.88 (2.64) 29.15 (2.62) 30.38 (2.77)
CaffVAS Overall
Mood
Placebo 60 82.10 (1.84) 77.27 (2.26) 77.05 (2.04)
(PRE) Green Blend 60 79.42 (1.87) 76.53 (2.47) 74.93 (2.40)
 CGA 60 79.35 (2.36) 76.37 (2.58) 75.80 (2.48)
CaffVAS Overall
Mood
Placebo 60 73.12 (2.76) 73.20 (2.54) 72.62 (2.63)
(POST) Green Blend 60 74.35 (2.32) 71.97 (2.74) 69.28 (2.96)
 CGA 60 74.97 (2.46) 72.78 (2.45) 71.68 (2.56)
doi: 10.1371/journal.pone.0082897.t004
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Figure 3.  Significant Treatment effects on Mood Measures.  † p<.10, * p<.05, p<.01.
doi: 10.1371/journal.pone.0082897.g003
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Caffeine-VAS Tired.  Box-cox transformation was applied to
pre-test Tiredness scores (Lambda = +0.5) in order to
normalize the data prior to analysis. ANCOVA adjusting for
baseline scores and considering time, treatment and their
interaction as independent variables were fitted for Caff-VAS
Tired scores both before cognitive testing (pre-test) and after
cognitive testing (post-test). Pre-test no significant treatment
effect or interaction with time was found. However, post-test a
significant interaction between treatment and time was found
(F(2,59)=3.79,p=.03). Differences of Least Square Means
revealed that at 40 minutes Tiredness was significantly lower
with CGA in comparison to placebo (t=2.53,p=.04, d=0.46).
Caffeine-VAS Mental Fatigue.  Box-cox transformation was
applied to pre-test headache scores (Lambda = +0.5) in order
to normalize the data prior to analysis. ANCOVA adjusting for
baseline scores and considering time, treatment and their
interaction as independent variables were fitted for Caff-VAS
Mental Fatigue scores both before cognitive testing (pre-test)
and after cognitive testing (post-test). No significant treatment
effect or treatment by time interaction was found either pre or
post-test.
Caffeine-VAS Tense.  Box-cox transformation was applied
to pre-test tension scores (Lambda = +0.25) as well as post-
test tension scores (Lambda = +0.5) in order to normalize the
data prior to analysis. ANCOVA adjusting for baseline scores
and considering time, treatment and their interaction as
independent variables were fitted for Caff-VAS Tense scores
both before cognitive testing (pre-test) and after cognitive
testing (post-test). Pre-test there was a trend towards an
interaction between treatment and time (F(2,59)=3.03,p=.06).
Differences of Least Square Means revealed that at 120
minutes there was a trend towards Caff-VAS Tense scores
being lower with decaffeinated green blend coffee in
comparison to placebo (t=2.36,p=.07, d=0.43). Post-test no
significant treatment effect or treatment by time interaction was
found.
Caffeine-VAS Jittery.  Box-cox transformation was applied
to pre-test Jitteryness scores (Lambda = +0.25) as well as
post-test content scores (Lambda = +0.25) in order to
normalize the data prior to analysis. ANCOVA adjusting for
baseline scores and considering time, treatment and their
interaction as independent variables were fitted for Caff-VAS
Jittery scores both before cognitive testing (pre-test) and after
cognitive testing (post-test). Pre-test there was a trend towards
a main effect for Treatment (F(2,59)=2.46,p=.09). Differences
of Least Square means revealed a trend towards decreased
Jitteriness with decaffeinated green blend coffee in comparison
to placebo at 40 minutes (t=2.24,p=.06, d=0.41) and with CGA
in comparison to placebo at 40 minutes (t=2.20,p=.06, d=0.40).
Post-test there was a trend towards an interaction between
treatment and time (F(2,59)=3.13,p=.05), however no
significant between-group differences were found with least
square means.
Caffeine-VAS Headache.  Box-cox transformation was
applied to pre-test headache scores (Lambda = 0, LN) as well
as post-test content scores (Lambda = 0, LN) in order to
normalize the data prior to analysis. ANCOVA adjusting for
baseline scores and considering time, treatment and their
interaction as independent variables were fitted for Caff-VAS
Headache scores both before cognitive testing (pre-test) and
after cognitive testing (post-test). Pre-test no significant
treatment effect or interaction with time was found. However,
post-test a significant interaction between treatment and time
was found (F(2,59)=5.93,p=.005). Differences of Least Square
Means revealed that at 120 minutes Caff-VAS Headache
scores were significantly lower with decaffeinated green blend
coffee in comparison to placebo (t=2.51, p=.03, d=0.46) and
with CGA in comparison to placebo (t=2.43, p=.04, d=0.44).
Caffeine-VAS Overall Mood Score.  Box-cox
transformation was applied to pre-test headache scores
(Lambda = +2.5) as well as post-test content scores (Lambda =
+2) in order to normalize the data prior to analysis. ANCOVA
adjusting for baseline scores and considering time, treatment
and their interaction as independent variables were fitted for
Caff-VAS Mood scores both before cognitive testing (pre-test)
and after cognitive testing (post-test). No significant main




No significant effects on cognition due to CGA were
observed at either 40 minutes or 120 minutes post-dose when
compared to placebo. However, there was a trend for CGA to
have some negative effects on attention and the speed that
information was processed. Specifically, for the RVIP task;
whilst no significant effects were found for the primary outcome
measure RVIP accuracy, at 120 minutes there was a trend
towards CGA consumption being associated with slower RVIP
reaction time in comparison to placebo. Similarly, for the
Inspection time task at 120 minutes there was a trend towards
CGA being associated with longer Inspection time (slower
information processing speed) in comparison to Placebo. No
other cognitive effects were observed.
There were few significant CGA mood effects when
compared to placebo. Specifically, at 40 minutes (post-
cognitive testing), Bond-Lader Content ratings were
significantly lower with CGA compared to Placebo (This was
corroborated with an overall trend towards lower Content
ratings following CGA compared to placebo, irrespective of
time). In relation to the Caffeine-VAS questionnaire, at 120
minutes (post- cognitive testing), ratings of Headache
symptoms were significantly lower following CGA consumption
in comparison to placebo. No other significant mood effects
were observed. However, there was a trend towards
participants being less jittery following CGA consumption,
irrespective of time and at 40 minutes (pre- cognitive testing)
specifically. Finally, for the Caffeine-VAS Tiredness scale (prior
to cognitive testing), there was a trend towards a decrease in
reports of Tiredness at 40-minutes following consumption of
CGA in comparison to placebo. In summary, compared to
placebo, CGA tended to improve symptoms of tiredness,
headaches and jitteriness, yet reduce ratings of contentedness.
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Effects of decaffeinated green blend coffee
No significant effects of decaffeinated NESCAFÉ Green
Blend coffee were found for the primary outcome measure
RVIP accuracy. However, compared to placebo decaffeinated
green blend coffee significantly improved reaction time on the
N-Back working memory task, which was corroborated with a
trend towards faster reaction time at both 40 minutes and 120
minutes post-dose. Similarly, for the Jensen-Box 2-choice task,
decaffeinated Green Blend coffee significantly improved
Decision Time at 40-minutes post-dose in comparison to
placebo. Interestingly, in the Jensen-Box 8-choice task, at 120
minutes there was a trend towards slower Decision Time
following consumption of decaffeinated green blend coffee in
comparison to placebo. No significant treatment effects were
found for serial subtraction with threes or sevens, or for the
Inspection Time task, suggesting that perhaps only specific
cognitive processes are enhanced by decaffeinated green
blend. It is also feasible that only the N-Back and the Jensen
Box tasks were sensitive enough to detect the subtle changes
in cognitive function associated with green blend coffee
consumption. In consideration of the fact that the Jensen task
is a highly sensitive measure of choice decision time (a
component of reaction time), it raises the possibility that lower
level cognitive aspects are acutely enhanced more than higher-
order cognitive functions with decaffeinated green blend coffee
consumption. However, this theory is difficult to reconcile with
the fact that improvements were also seen on the N-Back
continuous performance task, a task which subsumes both
storage and retrieval memory processes in addition to reaction
time (i.e. involves a range of cognitive processes including
higher order processing).
The most robust mood effect found to be associated with
decaffeinated green blend coffee consumption across both the
Bond-Lader and the Caffeine-VAS scales was of acute
increases in Alertness. Specifically, decaffeinated green blend
coffee improved Bond-Lader Alertness (trend level) at 40 and
120 minutes compared to placebo. This was supported with a
significant increase in alertness on the Caffeine-VAS at 120
minutes. It is interesting to note that this effect only emerged
after cognitive testing, rather than prior to testing, suggesting
that there may be an anti-fatigue effect associated with
decaffeinated green blend coffee which helps to maintain
Alertness under conditions of mental demand. These
improvements in subjective Alertness are in line with the
cognitive findings which indicate enhancement of choice
reaction time and sustained attention following decaffeinated
green blend coffee consumption. These findings also
corroborate the findings of our previous pilot study [27]
whereby green blend coffee was found to increase alertness in
comparison to regular decaffeinated coffee.
Also in line with the previous pilot study by Cropley et al.
[27], decaffeinated green blend coffee was found to
significantly decrease Caffeine-VAS Headache symptoms at
120 minutes. This effect was corroborated with an overall
trend-level reduction in reports of headache symptoms (post-
cognitive testing), when compared to placebo, irrespective of
time point. In addition, jitteriness, as measured with the
Caffeine-VAS, was found to be reduced (at trend level) with
decaffeinated green blend coffee compared to placebo (pre-
cognitive testing) at 40 minutes specifically and across both
time points combined. For the Caffeine-VAS Tiredness scale
(pre- cognitive testing), there was also a trend towards a
decrease in reports of Tiredness at 120-minutes following
consumption of green blend coffee in comparison to placebo.
Similarly, for Caffeine-VAS Tension, at 120 minutes (pre-
cognitive testing) there was a trend towards a decrease in
reports of Tension ratings with decaffeinated green blend
coffee compared to placebo. The finding of reductions in
Jitteriness and Headache symptoms following decaffeinated
green blend coffee consumption are intriguing. In consideration
of the fact that these symptoms are typically associated with
caffeine withdrawal it raises the possibility that decaffeinated
green blend coffee may help to ameliorate withdrawal
symptoms and that possibly the amelioration of caffeine
withdrawal may also assist in improving select indices of
cognition.
It is also possible that the very low doses of caffeine present
in both the green blend coffee and the CGA treatments (5 mg
and 8.8mg respectively) may have had minor effects on
amelioration of caffeine withdrawal symtoms. Whilst previous
research by Smit and Rogers [3] has suggested that doses as
low as 12.5mg caffeine may have effects on cognition and
mood following overnight caffeine abstinence, it is important to
note that these effects were only reported for heavy habitual
caffeine consumers. In consideration of the fact that low-
moderate caffeine consumers were included in the current
study, it is unlikely that levels of caffeine as low as 5mg would
have had a noticeable effect on cognitive function or withdrawal
symptoms. Similarly, differential treatment effects due to a
3.3mg caffeine difference between CGA and decaffeinated
green blend coffee are even less likely. To the best of our
knowledge no previous studies have investigated the effects of
caffeine on withdrawal with doses lower than 10mg. For
example, in a study by Heatherley et al. [30], caffeine
withdrawal effects following 8 hours of abstinence were
ameliorated using 1.2 mg/kg caffeine, which in a 70kg person
is equivalent to 84mg caffeine. Due to difficulties in removing
caffeine entirely from coffee, most decaffeinated coffees will
contain at least some proportion of caffeine. For instance, a
study by McCusker et al. [31] reported caffeine in the range
0-13.0mg/480g serve amongst 10 different decaffeinated
products. However, it is an important consideration that in
future studies concerning non-caffeine constituents as little
caffeine as possible should be included in the decaffeinated
preparations.
Are the positive effects of decaffeinated green blend
coffee attributed to the CGAs?
When compared to decaffeinated green blend coffee, CGA
produced an acute slowing of reaction time performance, as
measured by the slowing of Decision and Movement times on
the Jensen Box tasks. Specifically, in comparison to
decaffeinated green blend coffee, CGA was found to be
associated with worse performance on both the 2-choice and
4-choice Jensen task with an overall trend towards slower
Decision Times with CGA compared to green blend across
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both time points. Furthermore, in the 4-choice task, there was a
trend towards slower Decision Time at 40 minutes after
consuming CGA in comparison to decaffeinated green blend
coffee. This was corroborated with an overall trend towards
slower Movement Time with CGA compared to green blend on
the 4-choice Jensen task, irrespective of time and also at 120
minutes specifically. These results suggest that improvements
in cognitive performance observed with decaffeinated Green
Blend are not likely to be attributed to the CGAs.
Following cognitive testing, decaffeinated green blend Coffee
was found to significantly increase Bond-Lader Alertness
ratings in comparison to CGA irrespective of time. Furthermore,
when time was factored, decaffeinated green blend coffee
increased Alertness at 40 minutes (trend-level) and at 120
minutes (significant) compared to CGA. Corroborating the
findings from the Bond-Lader Alert scale, for the Caffeine-VAS
Alert scale (post- cognitive testing) subjects were also
significantly more alert after receiving green blend compared to
CGA across both time points. In addition, subjects receiving
CGA were found to be significantly less relaxed (Caffeine-VAS
scale) at 120 minutes (post- cognitive testing) in comparison to
those receiving decaffeinated green blend. Finally, for the
Caffeine-VAS Mental Fatigue scale, at 120 minutes (post-
cognitive testing) there was a trend towards higher ratings of
mental fatigue following CGA consumption in comparison to
Green Blend.
In summary, compared to placebo, both CGA and
decaffeinated green blend coffee tended to improve symptoms
of tiredness, headaches and jitteriness. However, no significant
differences were found between CGA and decaffeinated green
blend suggesting that it could be the CGAs found in the green
blend coffee that are attributed to these effects. However, the
acute improvement in subjective ratings of Alertness that was
observed with decaffeinated green blend was notably absent
following CGA consumption. In a number of other mood scales,
specifically Mental Fatigue and Relaxation, green blend also
outperformed CGA. Taken together these findings suggest the
CGAs may not be completely responsible for the proposed
anti-fatigue effect found with decaffeinated green blend coffee
and that other compounds in decaffeinated green blend coffee
are also contributing to the positive mood and cognitive effects.
While subtle differences exist in the Chlorogenic acid profile of
decaffeinated green blend and the CGA treatment in the
current study (see Table 1), it appears unlikely that 1-30 mg
differences in specific CGA components as part of a 6 gram
mixture would cause noticeable effects on cognition. A more
parsimonious explanation is that during the roasting of green
coffee beans, unique compounds are produced in addition to
CGAs which may also have acute effects on cognition.
Quinides are one such component produced during roasting
that may potentially modulate cognition actuely via effects on
blood glucose levels [32]. However, other changes in both the
anti-oxidant and anti-inflammatory profiles of coffee blends due
to total phenols and trigonelline content have also been
reported during roasting [33,34]. In future studies, investigation
into the acute cognitive effects of coffee constituents in addition
to chlorogenic acids are also warranted.
Conclusions
Whilst neither the decaffeinated green blend coffee or CGA
were found to have significant effects on the primary outcome
measure of RVIP accuracy when compared to placebo, a
number of significant treatment effects were found amongst the
secondary outcome measures. No evidence was found for
beneficial acute cognitive effects associated with CGA in the
current study. Rather, CGA was found to only have negative
effects on cognitive performance (specifically, attention (RVIP
task), speed of processing (IT task) and reaction time
performance (Jensons Box task) when compared to both
placebo and decaffeinated green blend coffee. In contrast,
compared to placebo, there was some evidence to suggest that
decaffeinated green blend coffee may bring about some
improvements to attention and reaction time performance, as
measured by the N-Back and Jensen Box task, respectively.
The contrast in findings regarding CGA and decaffeinated
green blend coffe suggest that any improvements to cognitive
performance that were observed with decaffeinated green
blend coffee are most likely not attributable to the CGAs.
In terms of mood, the results are more complicated to
interpret. CGA was found to improve subjective reports of
tiredness, headaches and jitteriness, yet reduce feeling of
content, when compared to placebo. These improvements
were similarly observed with decaffeinated green blend coffee
when compared to placebo. However, no significant differences
were found when comparing CGA and decaffeinated green
blend coffee directly. Thus, suggesting that it could be the
CGAs found in the green blend coffee that are attributed to
these positive mood effects, which could most parsimoniously
be associated with the amelioration of caffeine withdrawal
symptoms. In contrast, decaffeinated green blend coffee was
found to increase subjective reports of alertness when
compared to both placebo and CGA with small to moderate
effect size, suggesting that there are compounds in coffee
other than CGAs present in decaffeinated green blend coffee
which may exert an alerting effect.. This putative green blend
anti-fatigue effect is further corroborated with the increased
reports of relaxation and a reduction in feelings of mental
fatigue when compared to CGA. Thus taken together, the
results suggest that any improvements in cognitive function
that were found to be associated with decaffeinated green
blend coffee are most likely not attributable to the CGAs. Whilst
the decaffeinated green blend-related improvements in mood
appear to some extent to be attributable to the CGA content, it
appears likely that there are also other compounds in green
blend coffee that are contributing to the overall positive
cognitive and mood effects.
There are several recommendations for future research
based on the results and analyses of the present study. In
consideration of the large number of trend-level findings after
corrections for multiple comparisons were made, it is apparent
that the present study was under-powered. For this reason it
will be important to replicate certain aspects of the current
study using a larger sample – with power calculations based on
a considerably smaller effect size. In consideration of the
greater number of treatment effects that were found regarding
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the visual analogue mood scales in relation to the cognitive
tests it would also be appropriate to review the selection of
cognitive tests in future studies. It is a distinct possibility that
with an acute subtle effect on brain function such as that
associated with varying coffee constituents, mood effects are
easier to capture than cognitive improvements. In the current
study it was encouraging to see that two of the most sensitive
tests, the Jensen Box apparatus and the N-Back task, provided
the most consistent evidence of cognitive changes. The
inclusion of further tests that are of a similar nature to the
Jensen Box Task and N-Back task would perhaps maximise
the probability of capturing subtle cognitive changes in future.
Another issue is that individuals with varying Body Mass
Indexes (BMI) may have faster or slower rates of metabolism of
the active constituents. For this reason it would be worthwhile
for future research to consider administering doses that are
adjusted according to the subjects’ BMI. In a future study a
dose-escalation design using at least two differing levels of
CGAs could be beneficial to better understand the dose-
response characteristics associated with CGAs in coffee.
Finally, potential for acute cognitive effects associated with
coffee constituents other than chlorogenic acid, particularly
those produced during the roasting process, also warrants
further investigation.
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